Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NCF1 | P14598 | 1/20 | 0.35 |
| ▸ | EDNRA | P25101 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31447802 | 1.00 | NPC1 (0.47) | NPC1RAB9AUSP2TP53PKM | |
| SCHEMBL4278637 | 0.84 | NPC1 (0.58) | NPC1RAB9AUSP2TP53PKM | |
| SCHEMBL2218343 | 0.81 | ALDH1A1 (0.40) | NPC1RAB9AUSP2TP53PKM | |
| SCHEMBL5644795 | 0.78 | ALDH1A1 (0.33) | NPC1RAB9AUSP2TP53PKM | |
| SCHEMBL5646006 | 0.75 | KMT2A (0.44) | SMN1; SMN2GAAALDH1A1MAPTKMT2A | |
| SCHEMBL750364 | 0.74 | LMNA (0.36) | NPC1RAB9AUSP2TP53PKM | |
| SCHEMBL111337 | 0.74 | — | — | |
| SCHEMBL29367162 | 0.74 | — | — | |
| SCHEMBL7992483 | 0.73 | POLB (0.47) | ALDH1A1POLB | |
| SCHEMBL10968960 | 0.73 | JAK2 (0.31) | GAAALDH1A1MAPTKMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4713096-A1 | CDK INHIBITOR COMPOUNDS | Aleksia Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| WO-2024238574-A1 | CDK INHIBITOR COMPOUNDS | ALEKSIA THERAPEUTICS, INC. (US) | 2024-11-21 | — | — | WO | disclosed |
| US-20220402948-A1 | EGFR INHIBITOR, COMPOSITION AND PREPARATION METHOD THEREFOR | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2022-12-22 | — | — | US | disclosed |
| CN-110494431-B | Azacyclo derivative, preparation method and medical application thereof | 苏州浦合医药科技有限公司 | 2022-11-04 | — | — | CN | disclosed |
| WO-2021231400-A1 | BIS-ARYL ETHERS CONTAINING N-ACYL AZETIDINE AS EGFR/HER2 INHIBITORS | ACCUTAR BIOTECHNOLOGY, INC. (US) | 2021-11-18 | — | — | WO | disclosed |
| WO-2021057882-A1 | EGFR INHIBITOR, COMPOSITION AND PREPARATION METHOD THEREFOR | 贝达药业股份有限公司 | 2021-04-01 | — | — | WO | disclosed |
| US-10336729-B2 | 4-cyano-benzyl carbamimidoylcarbamate derivatives and their use as AOC3 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-07-02 | — | — | US | disclosed |
| EP-2300465-B1 | IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTEX THERAPEUTICS LTD (GB) | 2019-04-17 | — | — | EP | disclosed |
| WO-2019062657-A1 | NITROGEN HETEROCYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | 北京越之康泰生物医药科技有限公司 | 2019-04-04 | — | — | WO | disclosed |
| US-20190077790-A1 | 4-CYANO-BENZYL CARBAMIMIDOYLCARBAMATE DERIVATIVES AND THEIR USE AS AOC3 INHIBITORS | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2019-03-14 | — | — | US | disclosed |
| WO-2011147951-A1 | CYCLOAMINO DERIVATIVES AS GPR119 ANTAGONISTS | PROSIDION LIMITED (GB) | 2011-12-01 | — | — | WO | disclosed |
| EP-2035436-B1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2011-05-25 | — | — | EP | disclosed |
| US-20110020278-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-20100261727-A1 | 2-ARYLBENZOTHIOPHENE DERIVATIVES OR PHARCEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARCEUTICAL COMPOSITION FOR THE DIAGNOSIS OR TREATMENT OF DEGENERATIVE BRAIN DISEASE CONTAINING THE SAME AS ACTIVE INGREDIENT | Industry-University Cooperation Foundation Sogang University | 2010-10-14 | — | — | US | disclosed |
| US-20100261727-A1 | 2-ARYLBENZOTHIOPHENE DERIVATIVES OR PHARCEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARCEUTICAL COMPOSITION FOR THE DIAGNOSIS OR TREATMENT OF DEGENERATIVE BRAIN DISEASE CONTAINING THE SAME AS ACTIVE INGREDIENT | Industry-University Cooperation Foundation Sogang University | 2010-10-14 | — | — | US | disclosed |
| US-20100137302-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-06-03 | — | — | US | disclosed |
| EP-2035436-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma S.A. (BE) | 2009-03-18 | — | — | EP | disclosed |
| WO-2008001076-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2008-01-03 | — | — | WO | disclosed |
| US-4740505-A | INSECTICIDES, MITILIDES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1988-04-26 | — | — | US | disclosed |
| US-4002753-A | ANTIHYPERTENSIVE AGENTS | I.S.F. S.P.A. (IT) | 1977-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077790-A1 | 4-CYANO-BENZYL CARBAMIMIDOYLCARBAMATE DERIVATIVES AND THEIR USE AS AOC3 INHIBITORS | AOC3, AOC2, CBR3 | NPC1 1231/4885RAB9A 4378/4885USP2 1919/4885 |
| US-10336729-B2 | 4-cyano-benzyl carbamimidoylcarbamate derivatives and their use as AOC3 inhibitors | AOC3, AOC2, CBR3 | NPC1 1231/4885RAB9A 4378/4885USP2 1919/4885 |
| US-20100137302-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | PI4KA, PDPK1, PIK3CA | NPC1 4045/4885RAB9A 1177/4885USP2 3231/4885 |
| US-20100261727-A1 | 2-ARYLBENZOTHIOPHENE DERIVATIVES OR PHARCEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARCEUTICAL COMPOSITION FOR THE DIAGNOSIS OR TREATMENT OF DEGENERATIVE BRAIN DISEASE CONTAINING THE SAME AS ACTIVE INGREDIENT | APP, PSEN1, PSEN2 | NPC1 1589/4885RAB9A 4153/4885USP2 4304/4885 |
| US-20110020278-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, CYP2F1, CYP4F3 | NPC1 108/4885RAB9A 1700/4885USP2 4099/4885 |
| US-20220402948-A1 | EGFR INHIBITOR, COMPOSITION AND PREPARATION METHOD THEREFOR | EGFR, ERBB2, ERBB3 | NPC1 401/4885RAB9A 1918/4885USP2 4098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.